Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.

The transthyretin (TTR) amyloidoses are human diseases in which the misfolded TTR protein aggregates in tissues with subsequent visceral, peripheral, and autonomic nerve dysfunction. Recent reports have stressed the importance of oligomeric intermediates as major cytotoxic species in various forms of amyloidogenesis. We have examined the cytotoxic effects of several quaternary structural states of wild-type and variant TTR proteins on cells of neural lineage. TTR amyloid fibrils and soluble aggregates >100 kDa were not toxic. Incubation of TTR under the conditions of the cell assay and analysis by size-exclusion chromatography and SDS/PAGE reveal that monomeric TTR or relatively small, rapidly formed aggregates of a maximum size of six subunits were the major cytotoxic species. Small molecules that stabilize the native tetrameric state were shown to prevent toxicity. The studies are consistent with a model in which the misfolded TTR monomer rapidly aggregates to form transient low molecular mass assemblies (<100 kDa) that are highly cytotoxic in tissue culture.

[1]  J. Buxbaum Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? , 2003, Trends in biochemical sciences.

[2]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[3]  Joleen T White,et al.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.

[4]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[5]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[6]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Olofsson,et al.  Only amyloidogenic intermediates of transthyretin induce apoptosis. , 2002, Biochemical and biophysical research communications.

[8]  S. Müller,et al.  Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. , 2002, Journal of molecular biology.

[9]  James C. Sacchettini,et al.  Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.

[10]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.

[11]  J. Kelly,et al.  Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Kelly,et al.  Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. , 2001, Biochemistry.

[13]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[14]  Rui M. M. Brito,et al.  Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants* , 2001, The Journal of Biological Chemistry.

[15]  M. Saraiva,et al.  Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. , 2000, Journal of structural biology.

[16]  James C. Sacchettini,et al.  Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.

[17]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[18]  J. Kelly,et al.  Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[19]  J. Kelly,et al.  The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. , 1998, Current opinion in structural biology.

[20]  J. Buxbaum,et al.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.

[21]  P. Westermark,et al.  Characterization of intracellular amyloid fibrils in the human choroid plexus epithelial cells , 2004, Acta Neuropathologica.

[22]  D. Epps,et al.  Spontaneous Aggregation and Cytotoxicity of the β-Amyloid Aβ1–40: A Kinetic Model , 2003 .

[23]  J. Buxbaum,et al.  The genetics of the amyloidoses. , 2000, Annual review of medicine.